Author’s Note: This is an updated version of the post to our blog dated October 30, 2024. Later that day, FDA announced the resolution of Novo Nordisk’s semaglutide shortage, which altered the conclusion of our original post...more
11/4/2024
/ Administrative Procedure Act ,
DQSA ,
Drug Compounding ,
Enforcement ,
False Advertising ,
Food and Drug Administration (FDA) ,
Intellectual Property Protection ,
Lanham Act ,
Medical Devices ,
Monopolization ,
Patents ,
Popular ,
Proposed Rules ,
Regulatory Agenda ,
Supply Chain ,
Supply Shortages ,
Unfair Competition ,
Weight-Loss Products